ReNeuron Group (RENE): announces publication of positive Phase 2a data

Published on 17-02-2020 08:31:55
Author Sparks Team

ReNeuron Group announced the publication in a peer-reviewed journal of positive clinical data from the PISCES II Phase 2a clinical trial of its CTX stem cell therapy candidate for disability resulting from stroke.

Data from the study were originally presented by Professor Keith Muir at the American Heart Association International Stroke Conference 2018 (ISC 2018) in January 2018.

Olav Hellebø, ReNeuron’s CEO, commented: “We are delighted to see the positive results of the PISCES II clinical trial of our CTX cell therapy candidate for stroke disability published in this highly regarded peer-reviewed journal.”

Share this with friends and colleagues